Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$13.47M+2724.95%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pravin U. Dugel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 325
- Beta
- 0.97
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.00
Financials
Revenue
$13.47M+2724.9%Net Income
$-78.76MEBITDA
$-74.12MFree Cash Flow
$-70.64MEPS (diluted)
$-0.35Shares Outstanding (diluted)
224.95M+805.1%Operating Expenses
$93.57MCash & Debt
$598.64MReturn of Capital
$0.00Revenue by Segment (annual)
$51.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $51.82M | $-265.94M | $-1.42 |
| 2024 | $63.72M | $-193.51M | $-1.22 |
| 2023 | $58.44M | $-80.74M | $-1.09 |
| 2022 | $51.49M | $-71.04M | $-1.04 |
| 2021 | $43.52M | $-6.55M | $-1.05 |
| 2020 | $17.40M | $-155.64M | $-2.56 |
| 2019 | $4.23M | $-86.37M | $-1.91 |
| 2018 | $1.99M | $-57.69M | $-1.57 |
| 2017 | $1.92M | $-63.39M | $-2.20 |
| 2016 | $1.89M | $-44.70M | $-1.80 |
| 2015 | $1.75M | $-39.75M | $-1.71 |
| 2014 | $772.0K | $-28.65M | $-2.69 |
| 2013 | $0.00 | $-13.32M | $-4.52 |
| 2012 | $10.0K | $-14.09M | $-4.78 |
Valuation
OCULhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·5d ago·Negative
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
View source ↗ - Newsglobenewswire.com·35d ago·Negative
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
View source ↗ - Newsbenzinga.com·49d ago·Neutral
Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.36 per share
Typical surprise -11.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.35 vs $-0.40beat
- Tue, May 5$-0.41 vs $-0.32miss
- Thu, Feb 5$-0.29 vs $-0.33beat
- Tue, Nov 4$-0.37 vs $-0.39beat
- Tue, Aug 5$-0.39 vs $-0.35miss
- Mon, May 5$-0.37 vs $-0.29miss
Estimates and results for OCUL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OCUL officers and directors.
- Bought
- $461k
- Sold
- $3.8m
1 trade
34 trades
- Notman Donaldsold
- Kaiser Petersold
- Nayak Sanjaysold
- Heier Jeffrey S.sold
- Dugel Pravinsold
- Waheed Nadiasold
- Dugel Pravinsold
- Kaiser Petersold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OCUL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.